Other languages NEOVACS

Equities

Real-time Euronext Paris Other stock markets 09:20:05 2024-06-03 am EDT			5-day change	1st Jan Change
0.129 ^EUR	-10.42%		-64.29%	-93.55%

May. 29	Neovacs: mRNA approach validated in preclinical trial	CF
May. 27	Neovacs: collaboration contract with INSERM team	CF

Néovacs : approche ARNm validée en essai préclinique	May. 29
Néovacs : contrat de collaboration avec une équipe INSERM	May. 27
Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29
Reverse Split: 1 of 10000	Feb. 01	FA

No results for this search